R&D channel feed

#ASH20: Or­ca’s team show­cas­es their first cut of the da­ta on promis­ing cell pu­rifi­ca­tion work for HSCT

5 years ago

#ASH20 In a mul­ti­ple myelo­ma show­down, Re­gen­eron march­es out new PhI da­ta for its BC­MA bis­pe­cif­ic

5 years ago

#ASH20: As Bris­tol My­ers awaits FDA word, the CAR-T BC­MA lead­ers go head-to-head once again. This time, they're not alone

5 years ago
Cell/Gene Tx

#ASH20 Al­lo­gene's David Chang makes the case for an off-the-shelf CAR-T in the jam packed an­ti-BC­MA field

5 years ago
Cell/Gene Tx

#ASH20: Gilead­'s Kite reads out PhII da­ta to back CAR-T play­er Yescar­ta in a new in­di­ca­tion

5 years ago

#ASH20 Loxo and Eli Lil­ly show off PhI/II da­ta for their BTK in­hibitor in two blood can­cers

5 years ago

A decade af­ter it first failed, a Shire-de­vel­oped Take­da an­tivi­ral ap­pears suc­cess­ful in Phase III

5 years ago

BioN­Tech chief Ugur Sahin gains star sta­tus in the ex­clu­sive Cov­il­lion­aire club

5 years ago
People

Sutro's con­tin­ued PhI da­ta read­outs in­di­cate im­prov­ing re­sponse in ovar­i­an can­cer. What's next?

5 years ago

A high-pro­file ‘an­gel’ joins the Sil­i­con Val­ley crew back­ing an an­ti-ag­ing up­start with an eye on PhII

5 years ago
Financing

Jaz­z's $1B SCLC drug fails com­bo tri­al, quash­ing hopes of quick full ap­proval. But how much does it mat­ter?

5 years ago

Long af­ter Mer­ck and Bris­tol My­ers cre­at­ed a multi­bil­lion-dol­lar mar­ket, the PD-1 lead­ers are once again duk­ing it out — this time over a $12B-plus pot

5 years ago
Pharma

For two years, Ovid spun a Phase II miss as a win. The drug just failed Phase III

5 years ago

With eyes on an IPF fran­chise, Gala­pa­gos push­es sec­ond can­di­date in­to a dose-find­ing study

5 years ago

Af­ter Mod­er­na and Pfiz­er's stel­lar re­sults, the come­back play­ers at No­vavax face big ques­tions about their best-in-class hunt in a fren­zied Covid-19 vac­cine race

5 years ago
Coronavirus

Agios re­turns pos­i­tive PhI­II da­ta in a rare blood dis­or­der as it seeks to move past re­cent can­cer set­backs

5 years ago

FDA of­fers ‘break­through’ sta­tus for a HER2xHER2 bis­pe­cif­ic at the top of Zymeworks’ pipeline

5 years ago

Cap­ping Pas­cal So­ri­ot’s big turn­around, the an­a­lysts at Cowen say As­traZeneca is poised for a stel­lar year

5 years ago
Bioregnum
Opinion

Mod­er­na cal­i­brates fi­nal Covid-19 vac­cine ef­fi­ca­cy at 94.1% — and to­day it's gun­ning for the EUA

5 years ago
Coronavirus

Urovan­t's lead drug dis­ap­points in mid-stage study as first big FDA de­ci­sion looms

5 years ago

Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

5 years ago

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D pre­sen­ta­tion

5 years ago

Am­gen sev­ers 14-year Cy­to­ki­net­ics part­ner­ship, bail­ing on ome­cam­tiv af­ter mixed PhI­II re­sults

5 years ago

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

5 years ago
First page Previous page 181182183184185186187 Next page Last page
A service from the Financial Times